Apellis Pharmaceuticals, Inc.NASDAQ: APLS

Apellis Reports Pegcetacoplan Demonstrates Greater Treatment Responses and Quality-of-Life Improvements Compared to C5 Inhibitors for PNH

· Issued by Apellis Pharmaceuticals, Inc. via GlobeNewswire
Watch Apellis Pharmaceuticals explain itApellis Pharmaceuticals, Inc. (APLS) Q4 2025 Earnings Call · Replay · Feb 24
  • Data were presented at the American Society of Hematology (ASH) Annual Meeting
  • In an analysis from the 16-week Phase 3 PEGASUS study, 70.7% of patients treated with pegcetacoplan compared to 5.1% of eculizumab-treated patients achieved a good, major, or complete hematologic response based on published classifications
  • Quality-of-life substantially improved for pegcetacoplan-treated patients, reaching near-normal levels on several measures, and did not change for eculizumab-treated patients in a PEGASUS analysis at 16 weeks
  • A matching-adjusted indirect comparison suggests that 76% more patients on pegcetacoplan achieved hemoglobin stabilization and 71% more patients on pegcetacoplan were transfusion free compared to ravulizumab, a long-acting C5 inhibitor

WALTHAM, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced new analyses from the Phase 3 PEGASUS study, which demonstrated statistically significant improvements in treatment responses and substantial quality-of-life improvements with pegcetacoplan, an investigational, targeted C3 therapy, versus eculizumab, a C5 inhibitor, for paroxysmal nocturnal hemoglobinuria (PNH) at 16 weeks. Additionally, a matching-adjusted indirect comparison (MAIC) showed improvements in clinical, hematologic, and quality-of-life outcomes in patients treated with pegcetacoplan compared to ravulizumab, a long-acting C5 inhibitor. The data were presented at the virtual American Society of Hematology Annual Meeting (ASH) taking place December 5 - 8, 2020.

Substantial Improvements in Hematologic Responses and Quality-of-Life Demonstrated in Patients Treated with Pegcetacoplan Compared to EculizumabIn an analysis of hematologic responses from the PEGASUS study, using response classifications developed independently by PNH experts that were published in Frontiers in Immunology,1 the findings showed:

  • Approximately 70.7% of pegcetacoplan-treated patients (29/41) compared to 5.1% of eculizumab-treated patients (2/39) achieved a good, major, or complete hematologic response (p